Nirsevimab, a promising biologic for the passive inoculation of preterm infants against respiratory syncytial virus (RSV), has scored positive results in the Phase II/III MEDLEY trial.
Under development by AstraZeneca (LSE: AZN) and Sanofi (Euronext: SAN), the therapy is designed to be administered to preterm infants or those with chronic lung disease or congenital heart disease entering their first RSV season.
In the study, nirsevimab showed a similar safety and tolerability profile to Synagis (palivizumab), an injectable option for infants marketed by Swedish Orphan Biocitrum (STO: SOBI).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze